The synthetic pentasaccharide SR 90107 A/Org 31540 enhances tissue-type plasminogen activator-induced thrombolysis in rabbits

Fibrinolysis

Volumn 10, Issue 3, 1996, Pages 151-157

  Bernat, A ^a   Hoffmann, P ^a   Sainte Marie, M ^a   Herbert, J M ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOGEN; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; IODINE 125; PENTASACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FIBRINOLYTIC THERAPY; HEMATOLOGICAL PARAMETERS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RABBIT; THROMBOSIS;

EID: 0029900257     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80026-9     Document Type: Article

References (49)

1. Collen D, Stump D, Gold H. Thrombolytic therapy. Ann Rev Med 1988; 39: 405-20.
2. Fears R. Biochemical pharmacology and therapeutic aspects of thrombolytic agents. Pharmacol Rev 1990; 32: 201-22.
3. Goldhaber S Z. Thrombolysis for pulmonary embolism. Prog Cardiovasc Dis 1991; 34: 113-34.
4. Barr H, Lancashire M J, Torrie E P, Galland R B. Intra-arterial thrombolytic therapy in the management of acute and chronic limb ischemia. Br J Surg 1991; 78: 284-7.
5. Willerson J T, Golino P, McNatt J, Eidt J, Yao S K, Buja L M. Role of new antiplatelet agents as adjunctive therapies in thrombolysis. Am J Cardiol 1991; 67: 12A-18A.
6. Shen-Kun Y, Ober J, Ferguson J J, Maffrand J P, Anderson H V, Buja M, Willerson J T. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994; 267: H488-H493.
7. Yasuda T, Gold H K, Yaoita H et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb-IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-22.
8. Schulman S, Grinquist S, Wiman B, Lockner D. Thrombolysis and fibrinolytic parameters during heparin treatment of deep vein thrombosis. Thromb Res 1985; 39: 605-15.
9. Jun L, Arnout J, Vanhove P et al. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs. Coronary Artery Dis 1995; 6: 257-63.
10. Heras M, Chesebro J H, Penny W J et al. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988; 78: 654-60.
11. Badimon L, Badimon J J. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. J Clin Invest 1989; 84: 1134-44.
12. Chesebro J H, Fuster V. Dynamic thrombosis and thrombolysis. Role of antithrombins. Circulation 1991; 83: 1810-18.
13. Heras M, Chesebro J H, Penny W J, Bailey K R, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-65.
14. Hogg P J, Jackson C M. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-23.
15. Rucinski B, Niewiarowski S, James P, Walz D A, Budzynski A Z. Antiheparin proteins secreted by human platelets. Purification, characterization, and radioimmunoassay. Blood 1979; 53: 47-62.
16. Stassen J M, Rapold H J, Vanlinthout I, Collen D. Comparative effects of enoxaparin and heparin on arterial and venous clot lysis with alteplase in dogs. Thromb Haemost 1993; 69: 454-59.
17. Barradell L B, Buckley M M. Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992; 42: 858-8.
18. Choay J, Lormeau J C, Petitou M, Sinay P, Fareed J. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann NY Acad Sci 1981; 370: 644-9.
19. Thomas D P, Merton R E, Gray E, Barrowcliffe T W. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model. Thromb Haemost 1989; 61: 204-7.
20. Collen D, Stassen J M, Verstrate M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest 1983; 71: 368-76.
21. Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction. Value of combined thrombolytic and vasodilator therapy. N Engl J Med 1987; 317: 1055-9.
22. The GUSTO investigtors. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 1993; 329: 673-82.
23. Owen J, Friedman K D, Grossman B A, Wilkins C, Berke A D, Powers E R. Thrombolytic therapy with tissue-type plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616-20.
24. Eisenberg P R, Sherman L A, Jaffe A S. Paradoxic evaluation of fibrinopeptide A fter streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987; 10: 527-30.
25. Chesebro J H, Fuster V. Antithrombotic therapy for acute myocardial infarction: mechanisms and prevention of deep venous, left ventricular, and coronary artery thromboembolism. Circulation 1986; 74: III1-III10.
26. Topol E J, George B S, Kereiakes D J et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281-6.
27. Bleich S D, Nichols T C, Schumacher R R, Cooke D H, Tate D A, Teichman S L. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-17.
28. ISIS-2 (Second International Study of Infarct Survival). Collaborative study group randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,787 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
29. The SCATI group. Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989; July 22: 182-6.
30. Weitz J I, Hudoba M, Massel D, Maraganore J, Hirsh J. Clotbound thrombin is protected from inhibition by heparinantithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
31. Prager N A, Abendschein D R, McKenzie C R, Eisenberg P R. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995; 92: 962-7.
32. Hogg P G, Jackson C M. Heparin promotes the binding of thrombin to fibrin polymer. Quantitative characterization of a thrombus-fibrin polymer-heparin ternary complex. J Biol Chem 1990; 265: 241-7.
33. Hirsh J, Levine M N. Low-molecular-weight heparin. Blood 1992; 79: 1-17.
34. Nicolini F A, Nichols W W, Saldeen T G, Khan S, Mehta J L. Adjunctive therapy with low-molecular-weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis. Am Heart J 1992; 124: 280-8.
35. Mestre M, Uzan A, Sedivy P, Cavero I. Enoxaparain (Clexane®, Lovenox®), a low-molecular-weight heparin ehances t-PA-induced coronary thrombus lysis in anaesthetized dogs without inducing hypocoagulability. Thromb Res 1992; 66: 191-206.
36. Choay J, Lormeau J C, Petitou M, Sinay P, Fareed J. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann NY Acad Sci 1981; 370: 644-9.
37. Hobbelen P M, van Dinther T G, Vogel G M T, van Boeckel C A A, Moelker H C T, Meuleman D G. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasacchride) in rats. Thromb Haemost 1990; 63: 265-70.
38. Agnelli G A, Pascucci C, Cosmi B, Nenci G G. Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits. Blood 1990; 76: 2030-6.
39. Cerceck B, Lew A S, Hod H et al. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 74: 583-92.
40. Rapold H J, Lu H R, Wu Z, Nijs H, Collen D. Requirement of heparin for arterial and thrombolysis with recombinant tissue-type plasminogen activator. Blood 1991; 77: 1020-4.
41. de Bono D P, Simoons M L, Tijssen J et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122-8.
42. Tomaru T, Uchida, Y, Nakamura F, Sonoki H, Tsukamatu M, Sugimoto T. Enhancement of arterial thrombolysis with native tissue-type plasminogen activator by pretreatment with heparin or batroxobin: an angiographic study. Am Heart J 1989; 117: 275-81.
43. Agnelli G, Pascucci C, Cosmi B, Nenci G G. Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits. Blood 1990; 76: 2030-6.
44. Cercek B, Lew A S, Hod H, Yano J, Reddy N K, Ganz W. Enhancement of thrombolysis with heparin. Circulation 1986; 74: 583-7.
45. Vogel G M T, van Amsterdam R G M, Kop W J, Meuleman D G. Pentasaccharide and Orgaran® arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb Haemost 1993; 69: 29-34.
46. Nicolini F A, Lee P, Rios G, Kottke-Marchant K, Plowplol E J. Selective factor Xa inhibition facilities rt-PA-induced thrombolysis and prevents reocclusion in the electrolytic canine model. Eur Acad J 1994; 15: 2419-21.
47. Sitko G R, Ramjit D R, Stabilito I I, Lehman D, Lynch J J, Vlasuk G P. Conjunctive enhancement of enzymatic thrombolysis and prevention of reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Circulation 1992; 85: 805-15.
48. Rao A K, Pratt C, Berke A. Thrombolysis in myocardial infarction (TIMI) trial phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
49. Califf R M, Topol E J, George B S et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in the treatment of myocardial infarction. Am J Med 1988; 85: 535-9.